mRNA Therapy for Renal Fibrotic Signaling: A Clinical and Mechanistic Review

Abstract

Renal fibrosis is the final common pathway of chronic kidney diseases (CKD), leading to end-stage renal failure and significant morbidity and mortality worldwide. Recent advances have identified mRNA-based therapies as a promising frontier in targeting fibrotic signaling pathways within the kidney. This review synthesizes current knowledge on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, and management of renal fibrosis, with a special emphasis on the potential and challenges of mRNA therapeutics. We critically discuss recent evidence, emerging therapies, and guideline recommendations, providing clinicians and researchers with a comprehensive perspective on the integration of mRNA technology into future nephrology practice.

Introduction

Renal fibrosis is a progressive and irreversible process characterized by excessive deposition of extracellular matrix (ECM) and loss of functional renal parenchyma. It is the hallmark of most CKDs, regardless of etiology, and a key driver of progression to end-stage renal disease (ESRD). The limitations of current therapeutic options have prompted intense investigation into novel, mechanism-based therapies. In recent years, mRNA-based therapeutics, which harness the body’s translational machinery to modulate protein expression, have emerged as an innovative strategy for precise regulation of fibrotic signaling. This review aims to elucidate the scientific rationale, clinical relevance, and future potential of mRNA therapy for renal fibrosis, contextualized within the broader landscape of nephrology.

Epidemiology / Disease Burden

Chronic kidney disease affects nearly 10% of the global population, with fibrosis as the unifying pathological feature across various etiologies such as diabetes, hypertension, and glomerulonephritis. As renal fibrosis progresses, patients experience declining glomerular filtration rate (GFR), proteinuria, and ultimately, ESRD requiring dialysis or transplantation. The economic and social burden is immense, with direct healthcare costs and associated cardiovascular morbidity. Despite advances in renoprotective strategies, the prevalence of CKD is rising, underscoring the need for targeted antifibrotic interventions.

Pathophysiology

Renal fibrosis arises from a complex interplay of cellular and molecular events, including persistent injury, inflammation, and activation of profibrotic pathways. Central to this process is the activation of renal fibroblasts and pericytes, leading to myofibroblast transformation and ECM overproduction. Key molecular mediators include transforming growth factor-beta (TGF-β), connective tissue growth factor (CTGF), and components of the renin-angiotensin-aldosterone system (RAAS). mRNA therapy offers the potential to selectively modulate these signaling cascades by introducing synthetic mRNA sequences encoding antifibrotic or regulatory proteins, thereby restoring homeostasis at the molecular level.

Risk Factors

Risk factors for renal fibrosis parallel those of CKD and include poorly controlled diabetes, hypertension, chronic glomerulonephritis, recurrent urinary tract infections, and genetic predispositions such as polycystic kidney disease. Additionally, acute kidney injury (AKI) episodes can accelerate fibrotic transformation, especially in susceptible individuals. Environmental exposures, nephrotoxic drugs, and chronic inflammation further exacerbate the risk profile, emphasizing the need for early identification and intervention in high-risk populations.

Clinical Features

Clinically, renal fibrosis manifests as a gradual reduction in renal function, often presenting with asymptomatic proteinuria, hypertension, and eventually, symptoms of uremia as GFR declines. In advanced stages, patients may exhibit anemia, fluid overload, electrolyte imbalances, and complications of CKD-mineral and bone disorder (CKD-MBD). Imaging may reveal cortical thinning and increased echogenicity, while histological examination confirms interstitial fibrosis and tubular atrophy, the gold standard for diagnosis.

Diagnosis

Diagnosis of renal fibrosis relies on a combination of clinical, laboratory, and histopathological assessments. Biomarkers such as elevated urinary TGF-β, NGAL, and KIM-1 provide non-invasive clues to ongoing fibrotic activity, though their utility in routine practice is still evolving. Renal biopsy remains the definitive diagnostic tool, enabling direct visualization and quantification of fibrotic changes. Advanced imaging modalities, including diffusion-weighted MRI and elastography, are being evaluated for their ability to non-invasively monitor fibrosis progression and therapeutic response.

Treatment & Management

Current management strategies for renal fibrosis aim to control underlying etiologies, slow progression, and mitigate complications. Standard therapies include renin-angiotensin system inhibitors, strict glycemic and blood pressure control, and management of comorbidities. However, these approaches do not directly target the fibrotic process. Antifibrotic agents such as pirfenidone and bardoxolone methyl have shown limited efficacy in clinical trials, highlighting unmet therapeutic needs. mRNA-based therapy represents a paradigm shift, offering the potential for precise modulation of fibrotic signaling at the molecular level.

Recent Advances / Emerging Therapies

mRNA therapeutics have shown encouraging preclinical results in modulating renal fibrotic signaling. Preclinical studies indicate that synthetic mRNAs encoding antifibrotic proteins, such as BMP-7 or decorin, can effectively reduce fibrosis and restore renal function in animal models. Recent work also explores mRNA-mediated silencing of profibrotic mediators like TGF-β1 via RNA interference. Key challenges include targeted delivery to renal tissues, avoidance of immune activation, and sustained expression. Lipid nanoparticle (LNP) formulations and renal-targeted vectors are being optimized for efficient and safe mRNA delivery. Early-phase clinical trials are anticipated, with the hope of translating these breakthroughs into practice. Regulatory guidance is evolving, with a strong emphasis on safety, immunogenicity, and long-term efficacy.

Guideline Recommendations

While major nephrology guidelines recognize the importance of fibrosis in CKD progression, specific recommendations regarding mRNA therapy remain pending due to the nascent stage of clinical evidence. Current best practice emphasizes aggressive risk factor modification, use of RAAS blockade, and consideration of enrollment in clinical trials for novel antifibrotic agents. As mRNA therapeutics advance towards clinical translation, future guidelines will likely address patient selection, monitoring protocols, and integration with existing therapies, informed by robust clinical trial data.

Conclusion

Renal fibrosis represents a critical therapeutic target in chronic kidney disease, with profound implications for patient outcomes. mRNA-based therapies offer a novel and promising approach to modulate key fibrotic pathways, potentially transforming the landscape of nephrology. While significant challenges remain, including delivery, safety, and regulatory oversight, ongoing research and early clinical development provide optimism for the integration of mRNA therapeutics into standard care. Multidisciplinary collaboration between clinicians, researchers, and regulatory agencies will be essential to realize the full potential of this innovative modality for the benefit of patients with CKD.